Lipid profile after switching from TDF (tenofovir disoproxil)-containing to TAF (tenofovir alafenamide)-containing regimen in virologically suppressed people living with HIV

Background. Tenofovir disoproxil fumarate (TDF) or its prodrug tenofovir alafenamide fumarate (TAF) are currently being recommended in treatment of HIV infection. Distinct pharmacological properties of these two forms of a this drug make TAF treatment less nephrotoxic and lead to better impact on b...

Full description

Bibliographic Details

Published in:	Journal of Medical Science
Main Authors:	Michał Łomiak, Zofia Gajek, Jan Stępnicki, Agnieszka Lembas, Tomasz Mikuła, Alicja Wiercińska-Drapało
Format:	Article
Language:	English
Published:	Poznan University of Medical Sciences 2023-09-01
Subjects:	antiretroviral therapy tenofovir disoproxil fumarate tenofovir alafenamide lipids cholesterol low-density lipoproteins
Online Access:	https://jms.ump.edu.pl/index.php/JMS/article/view/808